Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAF ^V600E clone in a newborn affected by high-risk Langerhans cell histiocytosis.

Autor: Beneforti L; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.; Department of Pediatric Hematology Oncology, Meyer Children's Hospital IRCCS, Florence, Italy., Chinnici A; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.; Department of Pediatric Hematology Oncology, Meyer Children's Hospital IRCCS, Florence, Italy., Coniglio ML; Department of Pediatric Hematology Oncology, Meyer Children's Hospital IRCCS, Florence, Italy., Papa MR; Department of Oncology, Hematology and Cell Therapy, AORN Santobono-Pausilipon, Naples, Italy., Punzi L; Department of Translational Medical Sciences, Section of Pediatrics, University Federico II, Naples, Italy., Sieni E; Department of Pediatric Hematology Oncology, Meyer Children's Hospital IRCCS, Florence, Italy., De Fusco C; Department of Oncology, Hematology and Cell Therapy, AORN Santobono-Pausilipon, Naples, Italy.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Sep; Vol. 205 (3), pp. 1234-1237. Date of Electronic Publication: 2024 Jul 10.